Literature DB >> 27890708

Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.

Xiaodong Ding1, Sandeep K Barodia2, Lisha Ma1, Matthew S Goldberg3.   

Abstract

Dominantly inherited mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common causes of familial Parkinson's disease (PD) and LRRK2 polymorphisms are associated with increased risk for idiopathic PD. However, the molecular mechanisms by which these mutations cause PD remain uncertain. In vitro studies indicate that disease-linked mutations in LRRK2 increase LRRK2 kinase activity and LRRK2-mediated cell toxicity. Identifying LRRK2-interacting proteins and determining their effects on LRRK2 are important for understanding LRRK2 function and for delineating the pathophysiological mechanisms of LRRK2 mutations. Here we identified a novel protein, F-box and leucine-rich repeat domain-containing protein 18 (Fbxl18) that physically associates with LRRK2. We demonstrated that Fbxl18 is a component of a Skp1-Cullin1-F-box ubiquitin ligase complex that regulates the abundance of LRRK2 by selectively targeting phosphorylated LRRK2 for ubiquitination and proteasomal degradation. Knockdown of endogenous Fbxl18 stabilized LRRK2 abundance while protein kinase C activation enhanced LRRK2 degradation by Fbxl18. Dephosphorylation of LRRK2 blocked Fbxl18 association with LRRK2. Taken together, we have identified potential mechanisms for LRRK2 regulation by kinase signaling pathways. Furthermore, Fbxl18 prevented caspase activation and cell death caused by LRRK2 and PD-linked mutant LRRK2. This reveals novel targets for developing potential therapies for familial and idiopathic PD.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell death; Kinase; LRRK2

Mesh:

Substances:

Year:  2016        PMID: 27890708      PMCID: PMC5718210          DOI: 10.1016/j.nbd.2016.11.004

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  43 in total

Review 1.  A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways.

Authors:  T Maniatis
Journal:  Genes Dev       Date:  1999-03-01       Impact factor: 11.361

Review 2.  Parkinson's disease: insights from pathways.

Authors:  Mark R Cookson; Oliver Bandmann
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

3.  Systematic analysis and nomenclature of mammalian F-box proteins.

Authors:  Jianping Jin; Timothy Cardozo; Ruth C Lovering; Stephen J Elledge; Michele Pagano; J Wade Harper
Journal:  Genes Dev       Date:  2004-11-01       Impact factor: 11.361

Review 4.  LRRK2 in Parkinson's disease: protein domains and functional insights.

Authors:  Ignacio F Mata; William J Wedemeyer; Matthew J Farrer; Julie P Taylor; Kathleen A Gallo
Journal:  Trends Neurosci       Date:  2006-04-17       Impact factor: 13.837

5.  The application of proteomics for studying the neurorescue activity of the polyphenol (-)-epigallocatechin-3-gallate.

Authors:  Orly Weinreb; Tamar Amit; Moussa B H Youdim
Journal:  Arch Biochem Biophys       Date:  2008-01-13       Impact factor: 4.013

Review 6.  Phosphorylation of LRRK2: from kinase to substrate.

Authors:  Evy Lobbestael; Veerle Baekelandt; Jean-Marc Taymans
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

Review 7.  Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: a meta-analysis.

Authors:  Xi Wu; Ke-Fu Tang; Yang Li; Yu-Yu Xiong; Lu Shen; Zhi-Yun Wei; Ke-Jun Zhou; Jia-Min Niu; Xia Han; Lun Yang; Guo-Yin Feng; Lin He; Sheng-Ying Qin
Journal:  Parkinsonism Relat Disord       Date:  2012-05-08       Impact factor: 4.891

8.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.

Authors:  Elisa Greggio; Shushant Jain; Ann Kingsbury; Rina Bandopadhyay; Patrick Lewis; Alice Kaganovich; Marcel P van der Brug; Alexandra Beilina; Jeff Blackinton; Kelly Jean Thomas; Rili Ahmad; David W Miller; Sashi Kesavapany; Andrew Singleton; Andrew Lees; Robert J Harvey; Kirsten Harvey; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2006-06-05       Impact factor: 5.996

9.  Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.

Authors:  Xianting Li; Qing Jun Wang; Nina Pan; Sangkyu Lee; Yingming Zhao; Brian T Chait; Zhenyu Yue
Journal:  PLoS One       Date:  2011-03-01       Impact factor: 3.240

Review 10.  The F-box protein family.

Authors:  E T Kipreos; M Pagano
Journal:  Genome Biol       Date:  2000-11-10       Impact factor: 13.583

View more
  4 in total

1.  Identification by proximity labeling of novel lipidic and proteinaceous potential partners of the dopamine transporter.

Authors:  Dolores Piniella; Elena Martínez-Blanco; David Bartolomé-Martín; Ana B Sanz-Martos; Francisco Zafra
Journal:  Cell Mol Life Sci       Date:  2021-10-28       Impact factor: 9.261

2.  A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy.

Authors:  Wakako Nonaka; Tadayuki Takata; Hisakazu Iwama; Satoshi Komatsubara; Hideki Kobara; Masaki Kamada; Kazushi Deguchi; Tetsuo Touge; Osamu Miyamoto; Takehiro Nakamura; Toshifumi Itano; Tsutomu Masaki
Journal:  Mol Med Rep       Date:  2022-01-18       Impact factor: 2.952

Review 3.  Molecular Pathways Involved in LRRK2-Linked Parkinson's Disease: A Systematic Review.

Authors:  Ailyn Irvita Ravinther; Hemaniswarri Dewi Dewadas; Shi Ruo Tong; Chai Nien Foo; Yu-En Lin; Cheng-Ting Chien; Yang Mooi Lim
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

4.  Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.

Authors:  Evy Lobbestael; Chris Van den Haute; Francesca Macchi; Jean-Marc Taymans; Veerle Baekelandt
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.